Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma.

Abstract

The only currently validated treatment for advanced hepatocellular carcinoma (HCC) is sorafenib. However, sorafenib has been mainly studied in patients with HCC developed in cirrhotic liver. Chemotherapy might be more suitable for patients with HCC in non-cirrhotic liver. We report the case of a young woman with fibrolamellar HCC in a non-cirrhotic liver, with histologically proven metastatic ganglionary relapse after surgical resection of the primary tumour. Chemotherapy with gemcitabine and oxaliplatin (GEMOX regimen) achieved a complete response without relapse five years after discontinuation of chemotherapy. This exceptional case raises the question of clinical trials specifically designed for patients with HCC in non-cirrhotic liver.

• Authors: Pauline Gras, Stéphanie Truant, Valérie Boige, Laure Ladrat, Philippe Rougier, François-René Pruvot, Mohamed Hebbar
• Journal: Case reports in oncology (Case Rep Oncol) Vol. 5 Issue 1 Pg. 169-72 (Jan 2012) ISSN: 1662-6575 [Electronic] Switzerland
• PMID: 22666208 (Publication Type: Case Reports)